Overview
Sounding the Alarm: Protecting PAD Patients Post Revascularization from Recurrent Events
Symposium Highlights from CRT2022
Click the"View Activity" button to view this activity.
View ActivityActivity already occured. CME/CE is no longer available for this activity
Listen to this engaging discussion on the latest evidence for patients with peripheral artery disease (PAD) post-revascularization! Several interactive case presentations are covered by our expert cardiology and vascular surgeon faculty. Topics include the latest data, clinical implications, unanswered questions, and potential outcomes with the latest approaches for mitigating recurrent events in patients with PAD post-revascularization.
This activity is intended for interventional cardiologists, cardiologists, vascular surgeons, cardiothoracic surgeons, technologists, nurses, and other healthcare providers who care for patients with peripheral vascular disease.
Despite data limitations, clinicians have long relied on dual antiplatelet therapy (DAPT) following lower extremity revascularization in patients with symptomatic PAD. New evidence has shown the utility of dual pathway inhibition targeting both platelets and thrombin in patients with PAD. In August 2021, the FDA expanded the indication for rivaroxaban plus aspirin to include patients post lower-extremity revascularization due to symptomatic PAD.
The therapeutic promise and potential of rivaroxaban and aspirin to keep patients out of the hospital and protected from recurrent events is a game changer. In the face of a rapidly evolving standard of care, CME is critical to address unmet needs in the ongoing management of PAD patients who have already had at least one lower limb intervention but remain at very high risk for serious adverse events and death.
Upon completion of this activity, participants will be able to:
• Interpret the latest data on DOACs in PAD post-revascularization
• Optimize anticoagulant therapy for patients with PAD post-revascularization secondary to patient-specific factors (e.g. type of revascularization, comorbidities, concomitant medications)
• Interpret the latest data on DOACs in PAD post-revascularization
• Optimize anticoagulant therapy for patients with PAD post-revascularization secondary to patient-specific factors (e.g. type of revascularization, comorbidities, concomitant medications)
Supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.
Nihar Desai, MD, MPH
Associate Professor of Medicine
Yale School of Medicine
Vice Chief, Clinical Operations, Section of Cardiovascular Medicine
Investigator, Center For Outcomes Research and Evaluation
New Haven, CT
Associate Professor of Medicine
Yale School of Medicine
Vice Chief, Clinical Operations, Section of Cardiovascular Medicine
Investigator, Center For Outcomes Research and Evaluation
New Haven, CT
Anahita Dua, MD
Assistant Professor of Surgery
Harvard Medical School
Director of Vascular Lab
Co-Director of the Peripheral Artery Disease Center
Associate Director of the Wound Care Center
Massachusetts General Hospital
Boston, MA
Sandeep Nathan, MD, MSc, FACC, FSCAI
Associate Professor of Medicine
Medical Director, Cardiac Intensive Care Unit
Director, Interventional Cardiology Fellowship Program
Co-Director, Cardiac Catheterization Laboratory
The University of Chicago Medicine, Heart and Vascular Center
Chicago, IL
The Academy for Continued Healthcare Learning requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
Nihar Desai, MD, MPH
Consultant (Occasional): AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Vifor
Grant/Research Support recipient: Amgen, AstraZeneca, Boehringer Ingelheim, Cytokinetics, Vifor
Independent Contractor: Novartis
Anahita Dua, MBChB, MBA, MSc
Speaker Bureau: MiMedx, Penumbra, Inc.
Sandeep Nathan, MD, MSc, FACC, FSCAI
Consultant (Occasional): Janssen
Speaker Bureau: Janssen
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Dual antiplatelet therapy, aspirin, and clopidogrel for PAD
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 75 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
